Search results
Showing 31 to 45 of 235 results for radiotherapy
Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.
View recommendations for IPG268Show all sections
Sections for IPG268
Evidence-based recommendations on high dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer. This involves using radiotherapy to treat the cancer from both outside of the body and from within the affected area.
View recommendations for IPG174Show all sections
Evidence-based recommendations on low-level laser therapy for preventing or treating oral mucositis caused by radiotherapy or chemotherapy. This involves applying low-energy lasers to the affected tissue.
View recommendations for IPG615Show all sections
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (IPG784)
Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.
View recommendations for IPG784Show all sections
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)
This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatments are used.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
View recommendations for NG47Show all sections
Metastatic malignant disease of unknown primary origin in adults: diagnosis and management (CG104)
This guideline covers diagnosing and managing secondary cancer in people aged 18 and over when the site of the primary cancer is unknown. This includes people who have had treatment for cancer before. It aims to improve quality of life by offering advice on tests for identifying the site of the primary cancer and options for managing the person’s condition.
This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS17Show all sections
Sections for QS17
The section of the NICE impact lung cancer report looking at how the disease is treated.
Question How effective is stereotactic ablative radiotherapy compared with standard radiotherapy in the postoperative...
Question External beam radiotherapy compared with usual care: What is the clinical and cost effectiveness of external beam...
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma in adults.
View recommendations for TA489Show all sections
meningioma: immediate versus deferred radiotherapy for incompletely excised grade I meningioma:- Is immediate or deferred...